Justin Parizo, MD
Advanced Heart Failure and Transplant Cardiology · San Diego, CANPI 1023438637
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.8%), grants and food and beverage — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Bridgebio Pharma, Inc. at 47.8% of the total. 2025 is the largest year on record at $12,840, more than ten times the $23 reported in 2019.
Across 222 payments — averaging $109.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bridgebio Pharma, Inc.$12K
- Medtronic$8K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$764
- Abbott$542
- AstraZeneca$446
- Impulse Dynamics (USA) Inc.$394
- plus $3K from 22 others
Across 2 payments — averaging $39,800 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$80K
What the payments were for
- Speaking & faculty fees$10,38043%
- Grants$7,50031%
- Travel & lodging$1,0344%
- Food & beverage$5,20121%
- Education$1441%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bridgebio Pharma, Inc. | 10 | $11,604 |
| Medtronic(2 entities) | 4 | $7,775 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 40 | $764 |
| Abbott | 26 | $542 |
| AstraZeneca | 23 | $446 |
| Impulse Dynamics (USA) Inc. | 1 | $394 |
| Novartis | 23 | $370 |
| Abiomed | 4 | $367 |
| Merck | 13 | $327 |
| Actelion Pharmaceuticals US, Inc. | 17 | $305 |
| Alnylam Pharmaceuticals Inc. | 11 | $223 |
| Pfizer | 8 | $182 |
| E.r. Squibb & Sons, L.L.C. | 6 | $129 |
| Cvrx, Inc. | 5 | $109 |
| Boehringer Ingelheim | 6 | $108 |
| Heartflow, Inc. | 2 | $104 |
| Nuwellis, Inc. | 1 | $87 |
| Novo Nordisk | 3 | $84 |
| Irhythm Technologies, Inc. | 3 | $59 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $49 |
| Boston Scientific | 2 | $49 |
| Johnson & Johnson | 3 | $45 |
| Scpharmaceuticals Inc. | 2 | $38 |
| Kestra Medical Technology Services, Inc. | 2 | $33 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $15 |
| Altathera Pharmaceuticals LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,258 in reported general payments places this provider in the 65th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 16 | $521,861 |
| CamzyosMavacamten | 25 | $201,090 |
| EliquisApixaban | 106 | $134,276 |
| EntrestoSacubitril/Valsartan | 57 | $89,304 |
| JardianceEmpagliflozin | 62 | $85,086 |
| FarxigaDapagliflozin Propanediol | 65 | $79,650 |
| XareltoRivaroxaban | 16 | $26,427 |
| BrilintaTicagrelor | 16 | $8,796 |
| Ezetimibe | 64 | $3,938 |
| Metoprolol Succinate | 140 | $2,268 |
| Rosuvastatin Calcium | 57 | $1,792 |
| Atorvastatin Calcium | 160 | $1,732 |
| Carvedilol | 100 | $1,404 |
| Amlodipine Besylate | 190 | $1,368 |
| Spironolactone | 116 | $1,322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $182 | $656,136122 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $129 | $201,09025 claims |
| NovartisEntresto | $370 | $89,30457 claims |
| AstraZenecaFarxiga, Brilinta | $446 | $88,44681 claims |
| Boehringer IngelheimJardiance | $108 | $85,08662 claims |
| Johnson & JohnsonXarelto | $45 | $26,42716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in San Diego
- Hirsch MehtaSan Diego$494K
- Marcus UreySan Diego$341K
- Barry GreenbergSan Diego$270K
- Brian JaskiSan Diego$235K
- Ajay SrivastavaSan Diego$203K
- Jorge Silva EncisoSan Diego$164K
- Burhan MohamedaliSan Diego$154K
- Hao TranSan Diego$147K
- Eric AdlerSan Diego$24K
- Peter HoaglandSan Diego$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.